E
CHRS icon

Ergoteles’s Coherus Oncology CHRS Stock Holding History

Ergoteles’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,600
Closed -$70.9K – 183
2023
Q2 		$70.9K Buy
+16,600
New +$97.9K ﹤0.01% 937
2022
Q2 		– Sell
-44,704
Closed -$577K – 1678
2022
Q1 		$577K Buy
44,704
+4,687
+12% +$59.6K 0.02% 617
2021
Q4 		$639K Buy
40,017
+26,417
+194% +$462K 0.02% 551
2021
Q3 		$219K Buy
+13,600
New +$199K 0.01% 938

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ergoteles's CHRS Position: Q3 2023 in Review

Ergoteles sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 16,600 shares — an estimated $70.9K sold.

Ergoteles first reported a position in CHRS in Q3 2021 and held it in 4 quarters. The position peaked at $639K in Q4 2021. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Ergoteles reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 16,600 Coherus Oncology shares in Q3 2023, an estimated $70.9K.
  • Ergoteles first reported a position in Coherus Oncology in Q3 2021 and held it in 4 quarters.
  • Ergoteles's Coherus Oncology position peaked at $639K in Q4 2021.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.